Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | TYK2 | P29597 | 9/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208477 | 1.00 | NTRK1 (0.51) | NTRK1TYK2PDE4DTGFBR1HPGD | |
| SCHEMBL18208206 | 0.91 | NTRK1 (0.47) | NTRK1TGFBR1HPGDCHRM4GSK3A | |
| SCHEMBL18208209 | 0.91 | NTRK1 (0.47) | NTRK1TGFBR1HPGDCHRM4GSK3A | |
| SCHEMBL18209028 | 0.90 | NTRK1 (0.47) | NTRK1TYK2TGFBR1HPGDCHRM4 | |
| SCHEMBL18209026 | 0.90 | NTRK1 (0.47) | NTRK1TYK2TGFBR1HPGDCHRM4 | |
| SCHEMBL18208475 | 0.89 | NTRK1 (0.52) | NTRK1TYK2PDE4DTGFBR1HPGD | |
| SCHEMBL18208473 | 0.89 | NTRK1 (0.52) | NTRK1TYK2PDE4DTGFBR1HPGD | |
| SCHEMBL18208411 | 0.88 | NTRK1 (0.44) | NTRK1TYK2PDE4DTGFBR1HPGD | |
| SCHEMBL18208418 | 0.88 | NTRK1 (0.48) | NTRK1TGFBR1HPGDCHRM4POLB | |
| SCHEMBL18208421 | 0.88 | NTRK1 (0.48) | NTRK1TGFBR1HPGDCHRM4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | claimed |
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | NTRK1 3217/4885TYK2 3631/4885PDE4D 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.